LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

11.5 -2.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.48

Max

11.9

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+169.62% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-331M 1B
Vorige openingsprijs	14.29
Vorige sluitingsprijs	11.5

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 jun 2026, 21:51 UTC

Belangrijke Marktbewegers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Marktinformatie

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Marktinformatie

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Marktinformatie

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Marktinformatie

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Acquisities, Fusies, Overnames

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Marktinformatie

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Marktinformatie

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Marktinformatie

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Marktinformatie

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Acquisities, Fusies, Overnames

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Winsten

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Winsten

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Marktinformatie

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Winsten

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Marktinformatie

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Winsten

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Marktinformatie

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Marktinformatie

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Marktinformatie

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

169.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 169.62%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.